Compare Futu Holdings Ltd (FUTU) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Futu Holdings Ltd vs Recursion Pharmaceuticals Inc — how do they compare? Futu Holdings Ltd trades at $110.22 (market cap $15.38B), while Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.31B). The key difference: Futu Holdings Ltd is far larger — about 6.7× Recursion Pharmaceuticals Inc's market cap, and Futu Holdings Ltd pays a 2.37% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Futu Holdings Ltd for 34 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| FUTU | RXRX | |
|---|---|---|
Market Cap | $15.38B | $2.31B |
Volume | 1,475,116 | 40,478,768 |
Sector | Financials | Health |
52-Week High | $199.04 | $6.79 |
52-Week Low | $89.76 | $2.84 |
Typical Hold Time | 34 Days | 22 Days |
Enterprise Value | $15.73B | $1.83B |
Dividend Yield | 2.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Futu Holdings (FUTU) trades at $108.76, down 3.93% on the day amid a bearish technical signal, though it remains above key support near $107. The company reported strong Q2 2026 earnings with a beat on EPS of $3.33 versus $2.98 expected, continuing robust revenue growth that reached $22.85 billion in 2025. However, a securities class action lawsuit deadline on August 25, 2026, adds near-term uncertainty.
The outlook is mixed: solid fundamentals with a low P/E of 10.95 and high net margin of 42.92% support upside potential, but technical weakness and legal overhangs pose risks. Analyst consensus is bullish with a 33.7% upside target, yet investors must weigh growth against litigation and market sentiment pressures.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
